Patient CL0196 had small cell carcinoma that transformed from an Epidermal Growth Factor Receptor (EGFR) mutant lung adenocarcinoma following anti-EGFR therapy and had a confirmed partial response (PR) after 8 weeks on treatment with an ongoing response at data cutoff (Fig. 1b). The gene discussed is EGFR; the disease is lung adenocarcinoma.